Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 18, 2015 (11 years ago)

MYCAMINE (micafungin sodium)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Product sterility cannot be guaranteed.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

MYCAMINE (micafungin sodium) 150MG, Packaged in 150ML Homepumps, Rx Only. SENTARA HOME HEALTH SENTARA RX, 535 Independence Pkwy ste.300, Chesapeake, VA 23320-5176.

Drug: Micafungin

Recalling firm
Sentara Enterprises
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0644-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Micafungin recalls

See all
Class II · Moderate risk

Micafungin for Injection

Labeling; Incorrect or Missing Package Insert: The package insert provided with the product does not include all required sections approved for this product. This includes aspects of Adverse Reactions, Drug Interactions and Use in Specific Populations.

Terminated Labeling / mix-up Xellia Pharmaceuticals USA, LLC NDC 70594-037-01 D-0757-2021
Class II · Moderate risk

Micafungin for Injection

Labeling; Incorrect or Missing Package Insert: The package insert provided with the product does not include all required sections approved for this product. This includes aspects of Adverse Reactions, Drug Interactions and Use in Specific Populations.

Terminated Labeling / mix-up Xellia Pharmaceuticals USA, LLC NDC 70594-036-01 D-0756-2021

Other recalls by Sentara Enterprises

All 2015 recalls
Class II · Moderate risk

Gentamicin

Lack of Assurance of Sterility: Product sterility cannot be guaranteed.

Terminated Sterility / contamination Sentara Enterprises D-0641-2016
Class II · Moderate risk

Solu-Cortef

Lack of Assurance of Sterility: Product sterility cannot be guaranteed.

Terminated Sterility / contamination Sentara Enterprises D-0640-2016